<DOC>
	<DOCNO>NCT00544778</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , ifosfamide , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . Chemoprotective drug , dexrazoxane , may protect normal cell side effect chemotherapy . Giving combination chemotherapy together dexrazoxane surgery may make tumor small reduce amount normal tissue need remove . Giving radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give combination chemotherapy together dexrazoxane follow surgery radiation therapy work treat patient advanced soft tissue sarcoma recurrent bone sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Dexrazoxane Followed Surgery Radiation Therapy Treating Patients With Advanced Soft Tissue Sarcoma Recurrent Bone Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate effectiveness neoadjuvant dose-dense chemotherapy comprise doxorubicin hydrochloride , ifosfamide , irinotecan hydrochloride combination dexrazoxane hydrochloride follow surgery radiotherapy patient advance soft tissue sarcoma recurrent bone sarcoma . - To evaluate toxicity regimen patient . - To compare duration disease-free overall survival patient advance soft tissue sarcoma receive therapy neoadjuvant basis historical control . - To evaluate laboratory correlate chemotherapy resistance cytotoxic agent use study . OUTLINE : Patients stratify type sarcoma ( soft tissue v bone ) , prior treatment ( untreated v treat ) , presence metastasis ( yes v ) . - Courses 1 2 : Patients receive doxorubicin hydrochloride dexrazoxane hydrochloride IV continuously 96 hour . Treatment repeat every 3 week 2 course . - Courses 3 4 : Patients receive ifosfamide IV 2 hour twice day ( every 12 hour ) day 1-3 . Treatment repeat every 3 week 2 course . - Courses 5 6 : Patients receive irinotecan hydrochloride IV 1 hour day day 1-5 8-12 . Treatment repeat every 3 week 2 course . Patients also receive filgrastim ( G-CSF ) subcutaneously day begin 3 day completion chemotherapy continue blood count recover . Patients undergo standard surgery radiotherapy . Patients undergo blood sample collection periodically correlative study . Samples analyze MDR ( multidrug resistance gene ) protein expression via immunoperoxidase staining . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , year thereafter .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Primary soft tissue sarcoma highrisk* recurrence , meet follow criterion : Previously untreated locally advanced , nonmetastatic disease Advanced ( metastatic ) disease amenable standard high priority investigational neoadjuvant therapy Recurrent bone sarcoma ( e.g. , osteogenic sarcoma , Ewing sarcoma , peripheral neuroectodermal tumor ) Must advance locally recurrent metastatic disease NOTE : *Highrisk define highgrade , deep fascia , &gt; 5 cm great dimension Measurable nonmeasurable disease require Prechemotherapy consultation surgery radiation oncology require formulation locoregional therapy No gastrointestinal stromal cell sarcoma No alveolar soft part sarcoma No symptomatic brain metastases No requirement anticonvulsant corticosteroid therapy PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 2 month Absolute neutrophil count ≥ 2,000/mm^3 Platelet count &gt; 120,000/mm^3 Creatinine clearance &gt; 50 mL/min Serum bilirubin ≤ 1.5 mg/dL SGOT SGPT ≤ 2.5 time upper limit normal Serum albumin ≥ 2.5 mg/dL LVEF ≥ 50 % MUGA scan Not pregnant nursing Fertile patient must use effective contraception No concurrent nonmalignant illness ( e.g. , cardiovascular , pulmonary , CNS disease ) poorly control currently available treatment severity investigator deem unwise patient enter study PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy recurrent ( local metastatic ) soft tissue sarcoma Prior chemotherapy recurrent bone sarcoma allow provided total dose doxorubicin hydrochloride ≤ 300 mg/m^2 No prior radiotherapy &gt; 25 % bone marrow At least 3 week since prior radiotherapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>Ewing sarcoma bone</keyword>
</DOC>